# Miv-cel CD19 CAR T-Cell Therapy Shows Efficacy and Safety in Stiff Person Syndrome

Page: https://stenobird.com/podcast/neurology-minute-15117/miv-cel-cd19-car-t-cell-therapy-shows-efficacy-and-safety-in-stiff-person-syndrome-2
Text version: https://stenobird.com/podcast/neurology-minute-15117/miv-cel-cd19-car-t-cell-therapy-shows-efficacy-and-safety-in-stiff-person-syndrome-2.md
Podcast: [Neurology Minute](https://stenobird.com/podcast/neurology-minute-15117)
Published: 2026-06-11T08:30:00+00:00
Episode link: https://neurologyminute.libsyn.com/miv-cel-cd19-car-t-cell-therapy-shows-efficacy-and-safety-in-stiff-person-syndrome-0
Audio file: https://traffic.libsyn.com/secure/neurologyminute/04_June_11th_2026_nm_v2.mp3?dest-id=1085030
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/neurology-minute-15117/episodes/miv-cel-cd19-car-t-cell-therapy-shows-efficacy-and-safety-in-stiff-person-syndrome-2
Duration seconds: 189

## Resource

Dr. Shuvro Roy and Dr. Amanda Piquet discuss a brief overview of stiff person syndrome, as well as the trial and the trial results. Read more about this abstract on the AAN we bsite . Show transcript: Dr. Shuvro Roy: Hi, this is Shuvro Roy from the University of Washington and welcome to today's Neurology Minute. I just wrapped a longer conversation with Amanda Piquet from the University of Colorado Anschutz School of Medicine. We were just talking about the recent Phase 2 trial evaluating Miv-cel Kyverna Therapeutics' anti-CD19 CAR T-cell therapy in patients with Stiff Person Syndrome. Amanda, would you mind taking us through a brief overview of SPS as well as the trial and their trial results? Dr. Amanda Piquet: So Stiff Person Syndrome, or SPS, is a rare disabling autoimmune neurologic disease with a major unmet need. About 80% of patients ultimately lose their mobility and we currently have no FDA approved therapies. Existing treatments like IVIG, rituximab, and plasmapheresis are all used off label, often requiring chronic dosing and frequently failing to stop progression. KYSA-8 is a registrational Phase 2 study of 26 patients with refractory SPS. Patients experienced rapid, statistically significant and clinically meaningful improvement across all primary and secondary endpoints. Primary endpoint was the timed 25-foot walk. And this improved by a median of 46% at 16 weeks. Of patients requiring walking aids at baseline, about two thirds no longer needed them by week 16 to complete that 25-foot walk. Some patients who had struggled to walk were even able to run again after treatment. Another key finding was that all patients discontinued chronic immune therapies and remained off treatment as of the last follow-up. From a safety standpoint, miv-cel was generally w…

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/neurology-minute-15117/episodes/miv-cel-cd19-car-t-cell-therapy-shows-efficacy-and-safety-in-stiff-person-syndrome-2/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/neurology-minute-15117/miv-cel-cd19-car-t-cell-therapy-shows-efficacy-and-safety-in-stiff-person-syndrome-2.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.